To overcome this issue, in this study, we aim to validate the therapeutic value of BPTF by itself and in combination with gemcitabine in PDA KRAS-driven tumours either in vitro or in vivo using preclinical immunodeficient and immunocompetent mouse models. Here, KRAS is linked to Patent ductus arteriosus.